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Abstract There is a concern regarding the risk of occult
leiomyosarcomas found at surgery for presumed benign fi-
broids. We sought to produce a comprehensive review of pub-
lished data addressing this issue and provide high-quality
prevalence estimates for clinical practice and future research.
A comprehensive literature search using the PubMed/
MEDLINE database and the Cochrane Library was per-
formed. Inclusion criteria were human studies, peer-reviewed,
with original data, involving cases for surgery in which
fibroid-related indications were the primary reason for sur-
gery, and histopathology was provided. Candidate studies
(4864) were found; 3844 were excluded after review of the
abstract. The remaining 1020 manuscripts were reviewed in
their entirety, and 133 were included in the Bayesian binomial
random effect meta-analysis. The estimated rate of
leiomyosarcomawas 0.51 per 1000 procedures (95% credible
interval (CrI) 0.16–0.98) or approximately 1 in 2000.
Restricting the meta-analysis to the 64 prospective studies
resulted in a substantially lower estimate of 0.12
leiomyosarcomas per 1000 procedures (95 % CrI <0.01–
0.75) or approximately 1 leiomyosarcoma per 8300 surgeries.
Results suggest that the prevalence of occult leiomyosarcomas
at surgery for presumed uterine fibroids is much less frequent
than previously estimated. This rate should be incorporated
into both clinical practice and future research.
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Introduction
Uterine fibroids, also known as leiomyomas or myomas, are a
significant gynecologic problem, affecting 70–80 % of all
women during their reproductive years. These tumors are of-
ten symptomatic, producing complaints of abnormal bleeding,
pain, and infertility in many of those afflicted. The disease
represents a large economic burden for the health care system
and significantly affects the quality of life of many with these
tumors [1].
Two primary procedures have been utilized over the last
century to treat myomas: the hysterectomy, for those who do
not wish to retain their uterus, and myomectomy for those
who wish to maintain uterine structure and function, often
for future reproduction. Traditionally, these procedures were
performed via a large abdominal incision (laparotomy), often
required by the large size of the fibroid uterus.
Less invasive surgical approaches have been advocated
and performed for many years, although with much less fre-
quency than laparotomy. The challenge for surgeons
performing these less invasive operations is the usual
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requirement to remove large amounts of tissue through small
apertures.
Manual morcellation via scalpel or other devices has been
available for decades, allowing the completion of hysterecto-
mies (and even myomectomies) involving quite large speci-
mens through a vaginal or mini-laparotomy route. The advent
of minimally invasive surgery (MIS) utilizing endoscopy ini-
tially provided a resurgence in morcellation. As MIS skills
improved among surgeons and as equipment improved in
concert with the enhanced surgical skills being developed,
endoscopic procedures for both hysterectomy and myomecto-
my increased in number and popularity. A key innovation
allowing the performance of these procedures endoscopically
was the development and utilization of the electromechanical
(or Bpower^) morcellator.
The US Food and Drug Administration (FDA) first ap-
proved an electromechanical morcellation device in 1995,
and a number now exist in the market. However, recently,
the FDA issued a statement discouraging the use of such de-
vices, citing safety concerns, chief among these being the
inadvertent dissemination of occult uterine cancer in patients
undergoing hysterectomy and myomectomy for presumed be-
nign leiomyomata [2]. Their stated prevalence for unsuspected
uterine sarcoma, based upon their review of the medical liter-
ature, was 1 in 352 for any sarcoma and 1 in 498 for
leiomyosarcoma.
We and others were concerned that the FDA figures might
not be the product of a comprehensive and systematic review.
In response, our group decided to further investigate the prev-
alence of uterine leiomyosarcoma among women undergoing
surgery for presumed fibroids with a thorough review of pub-
lished studies of myomectomy or hysterectomy performed for
the indication of symptomatic fibroids that included histopath-
ologic analysis of all tissue removed.
Sources
A literature search was initially performed using the
PubMed/MEDLINE database and the Cochrane Library.
The search was performed for all manuscripts published
after 1960 and all languages using the search terms
Bmyoma,^ Bleiomyoma,^ Bfibroid,^ Bhysterectomy,^
Bincidental malignancy,^ Bmyomectomy,^ Bneoplasm,^
Bl e i omyo s a r c oma ,^ Bi n c i d e n c e ,^ Bp a t h o l o gy,^
Bhistopathology,^ Bmorcellation,^ and Bcomplication.^
These terms were used alone and in combination. All
references found were evaluated for the inclusion and ex-
clusion criteria listed below and their bibliographies hand-
searched for other potentially relevant publications. One
author (EAP) conducted a preliminary review; all papers
deemed to meet inclusion and exclusion criteria were then
reviewed by at least one other author for categorization
(RF, JF, DLO). If a disagreement was found between
reviewers, a conference involving multiple reviewers
was used to reach a decision.
Study selection
Inclusion criteria encompassed publications involving
humans that were peer-reviewed. All publications were re-
quired to contain original data. Papers were included if they
involved cases for surgery (hysterectomy or myomectomy) in
which fibroid-related indications were the primary reason for
surgery. If this was the exclusive focus of the manuscript, then
all cases in the publication were extracted. If, however, there
were multiple indications for surgery, only those cases with a
fibroid-related primary indication were extracted and included
in the analysis. To avoid case reports, a minimum of five
subjects from an individual study was necessary for inclusion
in this review.
Only those manuscripts in which the postoperative histo-
pathologic findings were provided for all extracted patients
were included in the analysis. Manuscripts stating Ball speci-
mens were sent to pathology^ without final reports were
deemed inadequate for inclusion. If the histopathologic de-
scription of a leiomyosarcoma in any study was inconsistent
with the current World Health Organization (WHO) diagnos-
tic criteria, we noted this, but included it as a leiomyosarcoma
in our evaluable data [3] (see below).
Studies that initially searched their databases for a patho-
logic diagnosis of fibroids, then worked backward to uncover
the primary indications for surgery, were excluded. Similarly,
all prospective analyses that a priori excluded any patient with
malignancy were excluded from the review. All letters to the
editor, abstracts, and all other non-peer-reviewed publications
of data were omitted. In many cases, we found multiple re-
ports based on a single patient cohort or overlapping cohorts.
When this was encountered, we included only one of these
papers, with selection based on the following hierarchy of
priorities: the publication with the most comprehensive pre-
sentation of information with the most leiomyosarcomas, the
largest number of patients, or the one that was the most recent.
Studies in which Bsarcomas^ or Bmalignancies^ were found
but were not specified as Bleiomyosarcoma^ were excluded.
The first study adequate for inclusion was published in July,
1984; the final was published in September, 2014.
After a thorough search of the literature, 4864 candidate
studies were found. Of these, 3844 were excluded after review
of the abstract. The remaining 1020 manuscripts were
reviewed in their entirety. Of these, 887 were excluded after
not meeting the inclusion and exclusion criteria above. One
hundred thirty-three publications with 134 analyses (1 publi-
cation included both retrospective and prospective data) com-
prised our evidence base and were used in the final analysis as
they contained postoperative histopathologic information for
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all reported patients (Fig. 1) (Supplemental Digital Content 1:
Tables of all included studies and their characteristics).
Statistical methods
We conducted our meta-analysis using a Bayesian bino-
mial random effect specification (R 3.1.1; JAGS 3.3;
Supplemental Digital Content 2: Bayesian statistical de-
tails and model code). We estimated separate models for
prospective and retrospective studies and a model com-
bining both study types. Inference was performed directly
on posterior samples generated by Markov chain Monte
Carlo. We calculated the rate of leiomyosarcoma per
1000 cases using the posterior random effect mean and
constructed 95 % credible intervals (CrIs) using the pos-
terior 2.5 and 97.5 percentiles and on the probability
scale by applying the logistic retransformation to the pos-
terior mean of the random effect mean parameter. We
assessed heterogeneity on the log-odds scale by calculat-
ing the posterior mean of the random effect variance pa-
rameter τ2 and on the probability scale by applying the
logistic transformation to the posterior mean of the ran-
dom effect mean parameter μα±1.96τ.
For comparison with the FDA analysis, we used an unad-
justed binomial mixed model with exact 95 % confidence
intervals (CIs) (PROC GLIMMIX SAS 9.4).
Sensitivity analysis was conducted to determine whether
the conclusions were robust in the presence of small numerical
changes in events (leiomyosarcomas).
Results
a. Rate of occult leiomyosarcoma in surgery for presumed
fibroids
Sixty-four published prospective analyses were included in
this review: 38 as prospective cohorts [4–41] and 26 as part of
a randomized clinical trial [42–67]. Thirteen studies contained
more than 100 subjects, 34 included 25–99 subjects, and six
had less than 25 subjects. Thirty-five studies were limited to
myomectomies, 24 involved only hysterectomies, four studies
included patients having either, and one did not state the type
of surgery (Table 1). These analyses encompassed 5223 wom-
en, with three leiomyosarcomas being found. Only two pro-
spective analyses found a leiomyosarcoma [34, 36].
Seventy published analyses with retrospective cohorts
qualified for this review, encompassing a total of 24,970 pa-
tients [33, 68–136]. Forty-four cohorts contained more than
100 women, 19 had 25–99 subjects, and seven included less
than 25 women. Twenty-five reports were limited to myomec-
tomies, 33 involved only hysterectomies, and 12 included
women undergoing either (Table 1). Of these, 29 were noted
t o have l e i omyosa r comas po s t s u rg i c a l l y. The
leiomyosarcomas were found in 13 of the 70 retrospective
analyses [75, 79, 84, 98, 100, 101, 106, 114, 115, 124, 125,
128, 129].
Taken together, these 134 analyses reported 32
leiomyosarcomas in 30,193 women undergoing surgery
(Supplementa l Digi ta l Content 3: Tables of al l
leiomyosarcomas, sources, and their histopathology). A
forest plot of these studies can be seen in Fig. 2. The
meta-analysis of the 64 prospective analyses provided an
estimated prevalence of leiomyosarcoma to be 0.12 per
1000 surgeries (95 % credible interval <0.01–0.75) or
approximately 1 leiomyosarcoma per 8300 surgeries.
When restricted to the 70 retrospective analyses, the esti-
mated prevalence was 0.57 per 1000 surgeries (95 % CrI
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Fig. 1 PRISMA evaluation of studies








>100 patients 5 8 44
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<25 patients 6 11 7
Type of surgery
Myomectomy 12 23 25
Hysterectomy 13 11 33
Both 1 3 12
Unknown 1
Gynecol Surg (2015) 12:165–177 167
0.17–1.13) or approximately 1 leiomyosarcoma per 1700
surgeries. Meta-analysis of all 134 analyses estimated
prevalence to be 0.51 per 1000 surgeries (95 % CrI
0.16–0.98) or approximately 1 leiomyosarcoma for every
2000 procedures (Table 2). The posterior mean of the
random effect variance parameter τ2=1.375, which


















































































































































































































































































Fig. 2 Forest plot of included studies. Pro prospective cohort and randomized studies, Retro retrospective
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implies that there is 95 % probability that the 134 under-
lying true study-specific rates of LMS ranged between
0.09 and 4.50 per 1000 surgeries.
b. Sensitivity analysis
Sensitivity of our analysis was tested in a variety of
ways. First, seven leiomyosarcomas from three retrospec-
tive analyses uncovered in our search failed to meet cur-
rent diagnostic criteria. We correctly classified these seven
tumors as non-malignant and reran our analysis; the
resulting prevalence estimate from our complete evidence
base was essentially unchanged from the previous esti-
mate (Table 3).
Secondly, we tested the robustness of the estimates by
adding one leiomyosarcoma to either the largest or smallest
study reporting no such malignancies. This maneuver
changed the estimated rate per 1000 surgeries by 0.02–0.08
for the meta-analysis of all studies and by 0.01–0.24 per 1000
cases for the meta-analysis of prospective datasets only
(Table 3).
Finally, we investigated the responsiveness of our Bayesian
methodology to heterogeneity of observed rates among stud-
ies by reallocating the 32 observed leiomyomas to studies in
proportion to their sample size (two each to the six largest
studies and one each to the next 20 largest). This maneuver
minimizes heterogeneity in observed rates and therefore
should yield an estimate that approaches the crude calculated
rate (number of leiomyosarcomas/number of surgeries). This
was in fact the case (Table 3).
Discussion
This meta-analysis of the existing literature reveals an estimat-
ed prevalence of leiomyosarcomas in surgeries for presumed
fibroids that is substantially less than that previously estimat-
ed. For this reason, it is important to take a close look at how
the estimates were derived and what they mean clinically.
Rigorously conducted systematic review and meta-analysis
is widely recognized as among the highest standards of evi-
dence for informed medical decision-making [137]. When











All studies 133 0.51 0.16, 0.98 0.79 0.5, 1.26
Prospective studies 64 0.12 0, 0.75 0.48 0.14, 1.72
Retrospective studies 70 0.57 0.17, 1.13 0.87 0.52, 1.46
All studies, N≥100 57 0.55 0.17, 1.06 0.81 0.49, 1.33
Prospective studies, N≥100 13 0.06 0, 0.62 0.45 0.06, 3.15
Retrospective studies, N≥100 44 0.59 0.18, 1.15 0.85 0.5, 1.45
FDA dataset 9 1.86 0.7, 3.32 2.02 1.06, 3.84
Table 3 Sensitivity analyses
Dataset Posterior mean rate per 1000 95 % credible interval
All studies 0.51 0.16, 0.98
All studies; add 1 LMS case to largest study 0.59 0.21, 1.08
All studies; add 1 LMS case to smallest study 0.53 0.16, 1.02
All studies; reclassification based on histopathology 0.53 0.16, 0.99
Prospective studies 0.12 0, 0.75
Prospective studies; add 1 LMS case to largest study 0.36 0, 1.27
Prospective studies; add 1 LMS case to smallest study 0.13 0, 0.89
All studies; crude test rate 1.03 0.69, 1.43
All studies; actual crude rate 1.06 0.75, 1.50
LMS leiomyosarcoma
See text for explanation of adding LMS cases and reclassification.
Crude test rate involved adding 32 LMS to 31 largest studies
Actual crude rate is (number of LMS/number of total surgeries) for all studies
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assessing the rate of rare events, formal meta-analysis may
offer the only reliable and accessible approach. It is often
asked why crude rates calculated by summing the total num-
ber of events (in this case leiomyosarcomas) across studies
and dividing by the total number of observations (surgeries)
is not adequate for estimating the prevalence. The answer lies
in the fact that the aggregate of populations from multiple
studies is not the same as a single large population undergoing
sampling. The heterogeneity among studies for inclusion and
exclusion, confounders, and even definitions of risk factors
and outcomes leads to tremendous bias in calculating a crude
prevalence [138, 139]. In statistical terms, crude calculations
are only appropriate if [1] each study was an independent and
identically distributed measure of the overall population, and
[2] the variance of each study’s estimate is known [140]. The-
se conditions are rarely if ever met.
Heterogeneity among studies in a meta-analysis also dic-
tates the type of analytic approach. When included studies
investigate the same population with the same research ques-
tions and structure, a fixed effect model can be used. As the
vast majority of studies in this analysis were not designed to
estimate the prevalence of leiomyosarcomas in surgery for
presumed fibroids, some degree of statistical heterogeneity is
likely. Thus, a random effect meta-analysis, which assumes
that design differences lead each study to produce rates that
are different but related to the rate of the population of interest,
was the approach used here [141]. The estimated random ef-
fect variance parameter τ2=1.375 suggests substantial hetero-
geneity between studies. However, a high degree of statistical
variability between studies is to be expected in rare events
random effect meta-analysis given the large number of studies
with zero events (thus having arbitrarily negative log-odds).
Finally, there are a number of random effect models from
which to choose. Our choice was to use a Bayesian bino-
mial model, which has a number of advantages over clas-
sical meta-analysis techniques that are particularly important
given the complexities of estimating rare event rates [141,
142] (for details, see supplemental digital content 2). Bayes-
ian random effect meta-analysis has been used extensively
under such conditions for clinical decision-making and pol-
icy analysis [143].
The best available estimate for the rate of occult
leiomyosarcoma lies in the data collected prospectively: that
gathered from randomized trials and prospective cohort stud-
ies. In these investigations, the data collection is begun at a
predefined time point, consecutive cases are included
avoiding selection bias and patient exclusion, and the data
are uniformly collected for all surgeries throughout the dura-
tion of the study. In this review, the estimated prevalence of
leiomyosarcoma using only data derived from prospective
studies was 0.12 per 1000 surgeries, with a 97.5 % probability
of being less than 0.75 per 1000 surgeries. Our sensitivity
analysis suggests that this estimate is modestly sensitive to
adding an incremental case of leiomyosarcoma to the largest
study reporting zero events, as would be expected given the
sma l l n umbe r o f p r o s p e c t i v e s t u d i e s f i n d i ng
leiomyosarcomas.
Expanding the evidence to include retrospective studies
yields an estimated rate of 0.51 per 1000 surgeries, with
97.5 % probability of being less than 0.98 per 1000. Retro-
spective data collection and analysis has a number of inherent
biases, and these can affect the calculated prevalence in either
direction. Data that cannot be found when doing chart reviews
may not be representative of the entire study population but
rather may represent an enriched sample. Prevalence would be
underestimated if, for example, records of leiomyosarcomas
were more frequently undiscovered because of being moved
to hospital risk management files! Conversely, retrospective
studies are often initiated after the discovery of an index case
at an institution. If the ensuing study population then includes
the index case, the resulting bias will uniformly overestimate
rate of prevalence. In the case of leiomyosarcomas in fibroid
surgery, this definitely occurred in at least two published stud-
ies [79, 100]. It is reasonable to suspect that other retrospective
studies were also initiated in response to an index case but did
not report this reason.
Our prevalence estimates differ substantially from that cal-
culated in the FDA meta-analysis, which was 2.02 per 1000
surgeries. Our group has been asked why these differences are
so profound. They can be attributed to both the base of evi-
dence and the statistical methodology. To sort out the relative
contribution of each, we applied our Bayesian methods to the
FDA dataset and estimated a rate of 1.86 per 1000 surgeries
(95 % CrI 0.70–3.32), which is about 8 % lower than the
FDA’s rate (Table 2). Thus, while differences in methodology
accounted for some of the difference in estimated rates, differ-
ences in the evidence base accounted for a much larger share.
The evidence base used in this study differed from the
studies utilized by the FDA in a number of significant ways.
First, our search and screen protocol identified all papers
where surgery was being performed for presumed fibroids
and where histopathology results were explicitly provided
for every subject in the study. This strategy yielded 134 anal-
yses in 133 published studies.
In contrast, to obtain their evidence, the FDA performed a
targeted search using the search terms Buterine cancer^ AND
Bhysterectomy or myomectomy^ AND Bincidental cancer or
uterine prolapse, pelvic pain, uterine bleeding, and uterine
fibroids.^ Using uterine cancer as a required search term ne-
cessitates the presence of uterine cancer in the manuscripts
available for analysis, while those studies without uterine can-
cers would be overlooked. Indeed, this was the case: 8/9 stud-
ies found in their search contained at least one
leiomyosarcoma. Of the 133 published studies included in
our review, 118 had no leiomyosarcomas and thus would not
have appeared in the FDA’s targeted search.
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A second difference lies in the fact that only studies with
more than 100 subjects were included in the evidence base
compiled by the FDA; their reasoning was that this would
reduce bias from smaller studies. Recognizing the arbitrary
nature of any predefined size threshold, our preferred ap-
proach was to include eligible studies of all sizes, while
allowing for the Bayesian model to weigh each study accord-
ing to its size and degree of statistical heterogeneity.
Nevertheless, the number of studies included in our evi-
dence base with 100 or more observations was 57, a number
far greater than that of the FDA. Restricting our meta-analysis
approach to just these 57 prospective and retrospective studies
resulted in a prevalence estimate essentially unchanged from
our analysis of all 134 studies and approximately one-fourth
that of the FDA’s estimates: 0.55 per 1000 (95 % CrI 0.17 to
1.06) (see Table 2). Applying the sample size restriction to our
prospective-only dataset resulted in inclusion of 13 studies
and an estimated rate of 0.06 per 1000 (95 % CrI <0.01 to
0.62). Thus, even utilizing the same arbitrary study size re-
striction as the FDA, our more comprehensive database sig-
nificantly lowers the prevalence estimate from their original
report.
Third, the FDA included only studies that exclusively ex-
amined procedures performed for presumed leiomyomas; if
multiple indications were listed by the author of the study, it
was excluded from their evidence base and was unavailable
for analysis. However, many publications containing multiple
indications for surgery contained unequivocal information
about those women with a primary surgical indication of fi-
broids and the data were easily extractable. They were includ-
ed in our evidence base if the patients undergoing hysterecto-
my or myomectomy for fibroids were clearly identified, if
histopathology was performed on all cases, and if results were
explicitly provided.
Fourth, the FDA excluded all non-English articles from
consideration. We felt the inclusion of non-English publica-
tions made for a more comprehensive review of the subject
and thus included studies regardless of the language of
publication.
Fifth, the FDA included one non-peer-reviewed abstract
[144] and one letter to the editor [145] in their dataset. We
excluded these and other similar data, restricting our analysis
to peer-reviewed publications containing five or more appli-
cable subjects. Parenthetically, the letter to the editor included
in the FDA evidence base was written in English [145]. The
original data were reported in their entirety in a French lan-
guage publication. We excluded the letter to the editor but
found the original, peer-reviewed publication and included it
in our evidence base. There were three leiomyosarcomas pre-
sented in this study [101].
Finally, we note that in the FDA’s review of the nine studies
referenced, eight were retrospective studies [98, 100, 101,
106, 114, 124, 128, 144] and one was a report from
prospectively collected data [34]. Such a preponderance of
retrospective reports raises concerns of significant ascertain-
ment bias in the resulting prevalence rate. Our analysis
contained a sufficient number of prospective studies to allow
analysis restricted to only these, producing what we believe to
be the most appropriate evidence base fromwhich to calculate
prevalence.
An additional bias may affect the analysis in both our study
and that of the FDA.Many of the publications used were from
referral centers, where patients are often sent for surgery be-
cause of an increased suspicion of additional pathology; with-
out the ability to exclude such cases from the routine hyster-
ectomy or myomectomy for presumed fibroids, the rate of
sarcoma will be overstated. This could be compounded by
the known bias of non-publication of negative results. A group
looking for occult sarcomas with zero events in their study
would be less likely to submit for or be accepted for
publication.
Despite the comprehensiveness of this review, there are still
potential shortcomings of this type of assessment. First, due to
the large number of publications involving surgery for uterine
fibroids from around the world, it is possible that some went
undiscovered by our investigation. However, the large number
of studies evaluated and the breadth of contexts considered
suggest that such publications are few in number. Another
related concern would be that if only a few leiomyosarcomas
were overlooked, the calculated prevalence might change sub-
stantially. This is unlikely, however, due to the relatively small
changes in prevalence seen with our sensitivity analysis.
It is also possible that leiomyosarcomas were missed in the
surgeries performed due to incomplete removal of all fibroids
or inadequate histopathologic examination. While we do not
have evidence to estimate this rate, we believe this to be at
most a relatively rare phenomenon. Nevertheless, our sensi-
tivity analyses suggested robustness of our results, as there
were relatively small changes in estimated rates from the ad-
dition of an incremental case of leiomyosarcoma to one large
or small trial previously reporting no cases. There was also a
relatively small change when correctly categorizing seven be-
n ign tumors tha t were or ig ina l ly d iagnosed as
leiomyosarcomas.
Concern might also be expressed that the vast majority of
studies included in this analysis, including all prospective
studies and randomized controlled trials, were not designed
to address the issue of leiomyosarcoma prevalence in such
surgeries. Thus, inclusion criteria may have inadvertently
eliminatedmany subjects who would be at higher risk for such
malignancies. While this is undoubtedly the case with some
trials, the large number of studies and the widely varying
reasons for study performance speak against a systematic bias.
Age ranges were similar for all datasets and very few restricted
patient inclusion a priori to premenopausal women (Table 4).
Moreover, the wide-ranging study hypotheses suggest that the
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information obtained is applicable to real-world clinical situ-
ations where surgery is performed for uterine fibroids.
We note that during data extraction, studies were excluded
from our analysis when they stated that all specimens were sent
for histopathologic analysis, but the results were not included in
the publications. In these cases, we expect that the tumors were
benign, as surely an event such as an occult leiomyosarcoma
would warrant reporting. Excluding such studies potentially
underestimated benign cases in our study, but we believe that
our conservative approach and rigorous inclusion criteria in-
crease the credibility of our prevalence rate.
A final issue worth noting is that of the criteria for the
diagnosis of leiomyosarcoma. The criteria used today for
leiomyosarcoma are those adopted by the World Health Orga-
nization in 2003 [3]. These criteria indicate that a malignant
neoplasm composed of cells demonstrating uterine smooth
muscle differentiation with coagulative tumor cell necrosis
(not hyaline necrosis) is a leiomyosarcoma. If no such necrosis
exists, then the diagnosis is made only if the mitotic index is
≥10 mitoses per 10 high-power fields and there is diffuse,
moderate to severe cytologic atypia. The microscopic criteria
to meet each of the three requirements are quite specific.
Many of the leiomyosarcomas found in our search provided
histologic detail in the manuscript. Interestingly, 7 of the 32
Bleiomyosarcomas^ found in our search would, based on
current WHO criteria, not be so classified today (Table 5). Fur-
ther validation of their non-malignant nature is found in the fact
that none of the seven had recurrence following surgery. De-
spite convincing evidence that these seven tumors were not in
fact leiomyosarcomas, we have maintained the original diagno-
sis in our calculations. Our sensitivity analysis suggests these
mislabeled tumors had little impact on the estimated preva-
lence. Nevertheless, this factor highlights a potential bias in
utilizing data from older or less highly scrutinized studies: the
potential for overestimating prevalence of clinically relevant
leiomyosarcomas via misinterpretation of histopathology. Our
search for this review included manuscripts published after
1960, in an attempt to be as all-inclusive as possible. We found
no studies that met inclusion criteria between 1960 and 1983.
The FDA’s inclusion dates for studies were between 1980 and
2014, making comparison of these two analyses justifiable.
However, both reviews are likely to be overstating the number
of actual leiomyosarcomas uncovered.
While we have found that the prevalence of occult
leiomyosarcoma is less than previously estimated, this
does not negate the fact that such occult malignancies
can and do occur. Furthermore, a number of other malig-
nancies have been found at these surgical procedures. It is
ideal to diagnose a tumor accurately prior to deciding the
type of surgery that is appropriate. The more common
Table 4 Age distributions by
study type and histopathology Dataset Study number Premenopausal only Study mean ages Age range
Randomized trials 26 10 35.8–53.4 20–70
Prospective 38 4 28.9–67.4 20–83
Retrospective 70 0 32.6–59.6 19–91
Studies with leiomyosarcomas 14 0 32.6–48.0 21–81




Table 5 Tumors inconsistent with World Health Organization 2003 leiomyosarcoma criteria
Author/date type Leiomyoma sub-type Age (years) Pathology Recurrence
∞Leibsohn/1990 retro Atypical 36 6 mitoses/10 HPF, Bpoorly demarcated,^ cellular atypia NED 6 months
Atypical 48 7 mitoses/10 HPF, cellular atypia NED 16 months
∞Parker/1994 retro Atypical 30 Irregular infiltrative borders, mild nuclear atypia, 5–8 mitoses/10 HPF NED Byears^
Seki/1992 retro Mitotically active 33 6 mitoses/10 HPF, no cellular atypia NED 11 months
Mitotically active 34 5 mitoses/10 HPF, no cellular atypia NED 57 months
Mitotically active 43 8 mitoses/10 HPF, no cellular atypia NED 61 months
Mitotically active 43 9 mitoses/10 HPF, no cellular atypia NED 72 months
HPF high-powered field
Retro retrospective
∞ included in FDA analysis
NED no evidence of disease
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types of uterine cancers may be diagnosed preoperatively,
bu t t h e r e i s no accu r a t e way t o do so fo r
leiomyosarcomas. Many uterine leiomyosarcomas, particu-
larly in younger women, are diagnosed after the tumor has
been removed surgically. It was beyond the scope of this
analysis to detail or quantify the risk of other cancers in
surgery for presumed fibroids, but investigation should
continue for a more thorough elucidation of the risks of
all such tumors as well as the relative benefits of different
surgical approaches. We believe that such data will allow
more meaningful research into the decision analysis re-
quired for this complex clinical issue.
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